Medication info

Entensive EF Injection

Prescription medicationSolution
Ingredient · strength
L-Alanine›0.92g / 100mLL-Arginine›0.79g / 100mLGlycine›0.72g / 100mLL-Histidine›0.2g / 100mLL-Isoleucine›0.33g / 100mLL-Leucine›0.48g / 100mLL-Lysine Acetate›0.61g / 100mLL-Methionine›0.28g / 100mLL-Phenylalanine›0.33g / 100mLL-Proline›0.73g / 100mLL-Serine›0.43g / 100mLTaurine›0.065g / 100mLL-Threonine›0.29g / 100mLL-Tryptophan›0.13g / 100mLL-Tyrosine›0.026g / 100mLL-Valine›0.41g / 100mLGlucose Monohydrate›9.3g / 100mLSoybean Oil›0.87g / 100mLTriglycerides Medium-Chain›0.87g / 100mLPurified Olive Oil›0.72g / 100mLPurified Fish Oil (High Dose Omega-3 Fatty Acids)›0.43g / 100mL
Manufacturer / importer
Fresenius Kabi Korea Ltd.
Appearance
This medication consists of an inner bag and outer packaging made from plastic material for infusion, divided into three compartments, containing an oxygen absorber in between. Each inner bag compartment contains an amino acid solution and glucose.
Packaging
506 mL/bag [×6 (Component A: 331 mL, Component B: 102 mL, Component C: 73 mL)], 1012 mL/bag [×4 (Component A: 662 mL, Component B: 204 mL, Component C: 146 mL)]
Approval status
Active

MFDS item code 202203688 · Approved 2022.09.27 · Insurance code 650902151,650902152

Summary

Main use
Improvement of nutritional deficiencies (calories, amino acids, essential fatty acids, etc.)
Who uses it
Adults · Children
Adult dosage
The dose and infusion rate should be determined according to the patient's ability to eliminate fat, metabolize nitrogen and glucose, and nutritional requirements. The dose should be individualized based on the patient's condition, body weight, nutritional and energy requirements, and additional oral/enteral intake. The nitrogen requirement for maintaining body protein depends on the patient's condition (e.g., nutritional status and catabolic stress or anabolism). Children 12 years of age and older and adults - Patients with normal nutritional status or mild metabolic stress: 0.6-0.9 g/kg/day of amino acids (0.10-0.15 g/kg/day of nitrogen) - Patients experiencing moderate to severe metabolic stress, regardless of nutritional imbalance: 0.9-1.6 g/kg/day of amino acids (0.15-0.25 g/kg/day of nitrogen) - In very special cases (e.g., burns or marked anabolic states), the amount of nitrogen may be higher. Dose: A daily dose of 13-31 mL/kg of this medicine provides 0.85-2.0 g/kg of amino acids (0.14-0.32 g/kg of nitrogen) and 12-28 kcal/kg total energy (8-19 kcal/kg non-protein calories). This meets the requirements of most patients. In obese patients, the dose should be based on predicted ideal body weight. Infusion rate: The infusion rate should not exceed 1.5 mL/kg per hour (equivalent to 0.10 g/kg amino acids, 0.13 g/kg glucose, and 0.04 g/kg fat). Administration over 14-24 hours is recommended. Intradialytic parenteral nutrition (IDPN): In stable adult patients receiving chronic renal replacement therapy, the maximum infusion rate for intradialytic parenteral nutrition (IDPN) is 3.0 mL/kg per hour (equivalent to 0.20 g/kg amino acids, 0.25 g/kg glucose, and 0.09 g/kg fat). The IDPN dose should be determined according to the difference between oral food intake and recommended nutrient intake, unavoidable nutrient losses due to renal replacement therapy, and the patient's individual metabolic tolerance. IDPN is generally administered over 3-5 hours, depending on the patient's needs and the scheduled duration of each renal replacement therapy session. The maximum recommended daily dose remains unchanged (31 mL/kg). Maximum daily dose: The maximum daily dose depends on the patient's clinical condition and may vary from day to day. The maximum recommended daily dose is 31 mL/kg. The maximum recommended daily dose of 31 mL/kg provides 2.0 g/kg amino acids (0.32 g/kg nitrogen), 2.6 g/kg glucose, 0.9 g/kg fat, and 28 kcal/kg total energy (19 kcal/kg non-protein calories). Administration: Administer by intravenous infusion through a central vein.
Children's dosage
Children (2-11 years): Pediatric patients have greater variability than adult patients; therefore, adjust the dose regularly according to requirements, up to 31 mL/kg of this medicine daily. Infusion rate: The maximum recommended infusion rate is 1.8 mL/kg per hour (equivalent to 0.12 g/kg amino acids, 0.15 g/kg glucose, and 0.05 g/kg fat). Except in special circumstances, administration at the maximum recommended infusion rate requires careful monitoring, and the infusion time should not exceed 17 hours. Administration over 12-24 hours is recommended. Maximum daily dose: The maximum daily dose depends on the patient's clinical condition and may vary from day to day. The maximum recommended daily dose is 31 mL/kg. The maximum recommended daily dose of 31 mL/kg provides 2.0 g/kg amino acids (0.32 g/kg nitrogen), 2.6 g/kg glucose, 0.9 g/kg fat, and 28 kcal/kg total energy (19 kcal/kg non-protein calories).

Ingredients

Importer
Fresenius Kabi Korea Ltd.

Efficacy & effects

Improvement of nutritional deficiencies (calories, amino acids, essential fatty acids, etc.)

View approved original text

This medication is used to supplement calories, amino acids, essential fatty acids, and omega-3 fatty acids for children over 2 years of age and adults when oral or gastrointestinal nutritional supply is difficult or insufficient. It helps improve nutritional status and provides needed nutrients to assist patient recovery.

Dosage and Administration

Adult dosage

The dose and infusion rate should be determined according to the patient's ability to eliminate fat, metabolize nitrogen and glucose, and nutritional requirements. The dose should be individualized based on the patient's condition, body weight, nutritional and energy requirements, and additional oral/enteral intake. The nitrogen requirement for maintaining body protein depends on the patient's condition (e.g., nutritional status and catabolic stress or anabolism). Children 12 years of age and older and adults - Patients with normal nutritional status or mild metabolic stress: 0.6-0.9 g/kg/day of amino acids (0.10-0.15 g/kg/day of nitrogen) - Patients experiencing moderate to severe metabolic stress, regardless of nutritional imbalance: 0.9-1.6 g/kg/day of amino acids (0.15-0.25 g/kg/day of nitrogen) - In very special cases (e.g., burns or marked anabolic states), the amount of nitrogen may be higher. Dose: A daily dose of 13-31 mL/kg of this medicine provides 0.85-2.0 g/kg of amino acids (0.14-0.32 g/kg of nitrogen) and 12-28 kcal/kg total energy (8-19 kcal/kg non-protein calories). This meets the requirements of most patients. In obese patients, the dose should be based on predicted ideal body weight. Infusion rate: The infusion rate should not exceed 1.5 mL/kg per hour (equivalent to 0.10 g/kg amino acids, 0.13 g/kg glucose, and 0.04 g/kg fat). Administration over 14-24 hours is recommended. Intradialytic parenteral nutrition (IDPN): In stable adult patients receiving chronic renal replacement therapy, the maximum infusion rate for intradialytic parenteral nutrition (IDPN) is 3.0 mL/kg per hour (equivalent to 0.20 g/kg amino acids, 0.25 g/kg glucose, and 0.09 g/kg fat). The IDPN dose should be determined according to the difference between oral food intake and recommended nutrient intake, unavoidable nutrient losses due to renal replacement therapy, and the patient's individual metabolic tolerance. IDPN is generally administered over 3-5 hours, depending on the patient's needs and the scheduled duration of each renal replacement therapy session. The maximum recommended daily dose remains unchanged (31 mL/kg). Maximum daily dose: The maximum daily dose depends on the patient's clinical condition and may vary from day to day. The maximum recommended daily dose is 31 mL/kg. The maximum recommended daily dose of 31 mL/kg provides 2.0 g/kg amino acids (0.32 g/kg nitrogen), 2.6 g/kg glucose, 0.9 g/kg fat, and 28 kcal/kg total energy (19 kcal/kg non-protein calories). Administration: Administer by intravenous infusion through a central vein.

Children's dosage

Children (2-11 years): Pediatric patients have greater variability than adult patients; therefore, adjust the dose regularly according to requirements, up to 31 mL/kg of this medicine daily. Infusion rate: The maximum recommended infusion rate is 1.8 mL/kg per hour (equivalent to 0.12 g/kg amino acids, 0.15 g/kg glucose, and 0.05 g/kg fat). Except in special circumstances, administration at the maximum recommended infusion rate requires careful monitoring, and the infusion time should not exceed 17 hours. Administration over 12-24 hours is recommended. Maximum daily dose: The maximum daily dose depends on the patient's clinical condition and may vary from day to day. The maximum recommended daily dose is 31 mL/kg. The maximum recommended daily dose of 31 mL/kg provides 2.0 g/kg amino acids (0.32 g/kg nitrogen), 2.6 g/kg glucose, 0.9 g/kg fat, and 28 kcal/kg total energy (19 kcal/kg non-protein calories).

Precautions

This medication must be used strictly according to a physician's instructions. If fever, chills, skin rash, or difficulty breathing occurs during administration, discontinue use immediately. Caution is required for premature infants or very low-birth-weight babies as the components of this medication might not be properly eliminated from the body, posing a risk. Individuals allergic to fish, eggs, soybeans, peanuts, or those with hypersensitivity to any components of this medication should not use it. Patients with severe liver dysfunction, hyperlipidemia, blood coagulation disorders, or renal failure should also not be administered this medication. Children under 2 years of age should refrain from using this medication for safety. Use with caution in individuals with renal or liver dysfunction or those with diabetes, pancreatitis, or hypothyroidism. Use of this medication may lead to increased heart rate or difficulty breathing, and gastrointestinal symptoms such as nausea, vomiting, and loss of appetite may occur. Additionally, changes in blood pressure, fever, headache, and dizziness might appear, necessitating consultation with a physician if any such symptoms occur. Excessive use can lead to elevated triglyceride levels in the blood, resulting in a serious condition known as fat overload syndrome, hence blood lipid levels must be monitored during administration. This medication can raise blood sugar levels, so diabetic patients must manage their blood sugar rigorously and may require insulin administration. To reduce the risk of infection during administration, maintain a sterile state, particularly when infusing through a central vein, with careful catheter management. Regular blood tests along with monitoring of electrolytes and liver function during prolonged use of this medication are mandatory. The safety of this medication during pregnancy and breastfeeding has not been sufficiently verified. It should only be used when the benefits of treatment outweigh the risks. After administration, components of this medication may affect laboratory test results; hence it is advisable to undergo testing 5-6 hours post-administration. In case of overdose, reduce or discontinue the infusion rate, as there is no specific antidote and symptomatic treatment and careful monitoring are needed. Infusion should not be performed too quickly; it is safer to use an infusion pump for a steady rate of infusion. Do not mix this medication with other drugs, and do not use if the packaging is damaged or if the contents are discolored. Store at a cool place below 25 degrees Celsius and use as soon as possible after mixing. Always consult with a physician when using this medication, and notify them immediately if any adverse symptoms arise.

Side effects

fever, chills, rash, dyspnea, tachycardia, loss of appetite, nausea, vomiting, increased plasma enzyme levels, hypotension, hypertension, mild elevation of body temperature, dizziness, headache, anaphylaxis, skin rash, hives, flushing, heat sensation, cold sensation, cyanosis, pallor, pain, symptoms of lipodystrophy (hyperlipidemia, fever, fatty infiltration, jaundice, hepatomegaly, splenomegaly, anemia, leukopenia, thrombocytopenia, coagulopathy, hemolysis, reticulocytosis, abnormal liver function tests, coma), nausea, vomiting, chills, sweating, elevated body temperature, hyperglycemia, allergic reactions

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air ingress, at room temperature between 1 degree and 25 degrees Celsius. This method of storage helps maintain the medication's efficacy and prevents degradation.

Appearance and packaging

Appearance

This medication consists of an inner bag and outer packaging made from plastic material for infusion, divided into three compartments, containing an oxygen absorber in between. Each inner bag compartment contains an amino acid solution and glucose.

Package unit

506 mL/bag [×6 (Component A: 331 mL, Component B: 102 mL, Component C: 73 mL)], 1012 mL/bag [×4 (Component A: 662 mL, Component B: 204 mL, Component C: 146 mL)]

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.